Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Predictive Oncology Acquires zPREDICTA, Inc.
zPREDICTA has developed a patented tumor-specific 3D cell culture platform that is complementary to Predictive Oncology’s Artificial Intelligence (AI) platform developed by Helomics. zPREDICTA’s uniquely designed 3D culture systems create a tumor microenvironment that is closer to the patient’s
View HTML
Toggle Summary Predictive Oncology Reports Third Quarter Financial Results
EAGAN, Minn. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Results from the third quarter show strong potential for future growth, said Predictive Oncology (Nasdaq: POAI) today, announcing financial results for the quarter ended September 30, 2021 . All three of Predictive Oncology’s reportable segments
View HTML
Toggle Summary Predictive Oncology Launches Website Highlighting AI-Powered Cancer Research Advancements
Predictive Oncology is leveraging AI to streamline drug discovery and development, improve outcomes in clinical testing and forge a new frontier of cancer research MINNEAPOLIS , Oct. 19, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology , an oncology and cancer research company using big data and
View HTML
Toggle Summary Predictive Oncology Inc. Announces Newest Board Member
MINNEAPOLIS , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce that Raymond F. Vennare was elected to the Board of Directors,
View HTML
Toggle Summary Predictive Oncology Announces Results of Charter Amendment Proposal at Special Meeting
MINNEAPOLIS , Aug. 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that on August 17, 2021 , the stockholders approved an amendment to the
View HTML
Toggle Summary Predictive Oncology Reports Financial Results for Quarter Ended June 30, 2021, and Provides Business Update
MINNEAPOLIS , Aug. 11, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended June 30, 2021 , and provided an
View HTML
Toggle Summary Predictive Oncology Adjourns Special Meeting of Stockholders
MINNEAPOLIS , Aug. 11, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the Company’s Special Meeting of Stockholders, which was convened at
View HTML
Toggle Summary Predictive Oncology subsidiary, Helomics uses data from the 100,000 Genomes Project to better predict ovarian cancer outcomes
Initial results demonstrate that AI models of genomic data can predict cancer outcomes. This has the potential to help personalize ovarian cancer treatments and drive the discovery of new therapies. MINNEAPOLIS , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a
View HTML
Toggle Summary Predictive Oncology Inc.’s Subsidiaries Soluble Biotech Inc. and TumorGenesis Inc. are both constructing new GMP labs
MINNEAPOLIS , June 22, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , an AI-driven oncology and drug discovery company, announced today that two of their wholly owned subsidiaries, Soluble Biotech Inc. and TumorGenesis Inc. are both expanding their unique services by completing the
View HTML
Toggle Summary Predictive Oncology Announces Closing of $21.34 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
MINNEAPOLIS , June 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has completed the closing of
View HTML